# Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

> **NCT05265234** · PHASE4 · UNKNOWN · sponsor: **OptiSkin Medical** · enrollment: 15 (estimated)

## Conditions studied

- Eczema
- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab
- **DEVICE:** Optical Coherence Tomography
- **DEVICE:** Reflectance confocal microscopy

## Key facts

- **NCT ID:** NCT05265234
- **Lead sponsor:** OptiSkin Medical
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2023-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265234, "Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05265234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*